Aidoc Collaborates with NVIDIA | Objective – to Establish Guidelines for AI Adoption In Healthcare

Aidoc, a pioneering force in clinical AI, today announced it is co-developing with NVIDIA a Blueprint for Resilient Integration and Deployment of Guided Excellence (BRIDGE), a guideline that aims to accelerate AI adoption across the healthcare industry.

Slated for release in early 2025, this industry-first guideline will offer a robust, evidence-driven framework for seamlessly integrating AI into clinical workflows, helping healthcare organizations scale AI innovation with greater speed and confidence. The guideline will help establish clear pathways for healthcare systems to fully harness the potential of AI in improving patient outcomes.

Despite the approval of over 900 FDA-cleared AI tools for medical imaging, healthcare systems remain mired in fragmentation, operational inefficiencies and scalability issues. The BRIDGE guideline will provide a comprehensive, vendor-neutral roadmap, helping address these persistent challenges and empowering providers to unlock AI’s full potential.

Breaking Barriers to AI Adoption

A key challenge for many AI solutions has been the failure to scale effectively because critical considerations around integration were not addressed early enough in the development process. The BRIDGE guideline will provide healthcare systems with direction on addressing scalability and interoperability from the start, enabling the implementation of AI solutions across multiple sites simultaneously.

“AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively,” said Demetri Giannikopoulos, Chief Transformation Officer, Aidoc. “The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike.”

While many existing guidelines focus on governance, regulatory concerns and responsible development practices. BRIDGE will be specifically designed to help developers and healthcare providers consider the practicalities of real-world deployment. This comprehensive framework will empower organizations to navigate the complexities of AI adoption, from ideation to implementation and scalability across hospital systems.

How the Guidelines Will Drive AI Adoption

This guideline will enable healthcare systems to adopt and scale AI faster and more effectively by simplifying the design, validation, deployment, and monitoring of AI tools.

Key areas of focus include:

  • Standardized Validation: Ensuring AI solutions are rigorously tested for real-world use.
  • Interoperability: Facilitating seamless integration of AI tools from different vendors.
  • Scalable Deployment: Providing a roadmap for efficient AI expansion across hospital systems.
  • Continuous Monitoring: Offering best practices to maintain AI accuracy post-deployment.

The BRIDGE guideline will lay the groundwork for aligning to industry frameworks, like MONAI, to build the blueprint for the medical AI enterprise platform. MONAI, co-founded by academia and industry, including NVIDIA, in 2019, provides the essential tools for medical AI development, validation, and deployment, and provides a strong foundation for building the BRIDGE guideline. With more than three million downloads and currently being used in FDA-approved software-as-medical-device applications, MONAI and its standardization, interoperability and scalability is key to transformative solutions in healthcare.

Real-World Impact

The guideline will be developed through close collaboration with healthcare providers, academic partners, and industry leaders. This effort will leverage the expertise and experience from real-world AI initiatives to help ensure the framework is practical, actionable, and scalable. By focusing on real-world challenges in AI integration, the guideline aims to provide a comprehensive and adaptable approach for healthcare organizations.

Learn more about the BRIDGE Guideline including how to access it in 2025 and help shape the overall direction here.

SourceAidoc

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”